Bicara Therapeutics
(NASDAQ) BCAX
Bicara Therapeutics Financials at a Glance
Market Cap
$1.42B
Revenue (TTM)
$0.00
Net Income (TTM)
-$157.32M
EPS (TTM)
-$2.77
P/E Ratio
-7.78
Dividend
$0.00
Beta (Volatility)
1.68 (High)
Dividend
$0.00
Beta (Volatility)
1.68 (High)
Price
$21.50
Volume
200
Open
$21.72
Price
$21.50
Volume
200
Open
$21.72
Previous Close
$21.50
Daily Range
$21.31 - $21.98
52-Week Range
$8.48 - $24.25
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
1.68 (High)
Price
$21.50
Volume
200
Open
$21.72
Previous Close
$21.50
Daily Range
$21.31 - $21.98
52-Week Range
$8.48 - $24.25
Estimated Earnings Date
Aug 11, 2026
BCAX News
BCAX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Bicara Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
103
CEO
Claire Mazumdar, PhD, MBA
Website
www.bicara.comHeadquarters
Boston, MA 02116, US
BCAX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-32%
Return on Capital
-34%
Return on Assets
-28%
Earnings Yield
-12.85%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.42B
Shares Outstanding
65.70M
Volume
200
Avg. Volume
537.15K
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$155.60M
EBITDA
-$137.63M
Operating Cash Flow
-$106.83M
Capital Expenditure
-$280.00K
Free Cash Flow
-$107.11M
Cash & ST Invst.
$414.80M
Total Debt
$1.71M
Bicara Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.42B
N/A
Market Cap/Employee
$25.76M
N/A
Employees
55
N/A
Net Income
-$56.21M
-52.6%
EBITDA
-$56.16M
-52.8%
Quarterly Fundamentals
Total Cash
$539.75M
+16.8%
Total Debt
$1.44M
+143.8%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$301.00K
N/A
Short Term Debt
$1.14M
+92.9%
Return on Assets
-28.42%
N/A
Return on Invested Capital
-33.85%
N/A
Free Cash Flow
-$37.57M
-33.7%
Operating Cash Flow
-$37.51M
-33.5%